Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01339481 · ClinicalTrials.gov registry record
A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
A clinical trial, sponsored by Astellas Pharma.
- Completed
- Registry status
- 26
- Enrollment target
NCT01339481: Completed study, sponsored by Astellas Pharma.
NCT01339481 is a clinical trial that has completed, run by Astellas Pharma. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01339481 has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.
Interventions
- DRUG abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-10 |
What the finished NCT01339481 record still lists
NCT01339481 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which abatacept is the first listed.
NCT01339481 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01339481 about?
NCT01339481 is a clinical study titled "A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept". The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.
What is the current status of trial NCT01339481?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2011-02. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01339481?
The interventions under investigation include: abatacept (DRUG).
Who is sponsoring clinical trial NCT01339481?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia